Crowe K E, Bass J A, Young V M, Straus D C
J Clin Microbiol. 1982 Jan;15(1):115-22. doi: 10.1128/jcm.15.1.115-122.1982.
We analyzed sera from 28 patients with various types of malignancies for the occurrence of antibodies against exotoxin A of Pseudomonas aeruginosa and two Pseudomonas proteases. A total of 27 of these individuals were colonized or infected with P. aeruginosa at one time or another during the study, whereas the remaining patient was colonized with four non-P. aeruginosa species of Pseudomonas. Sera were obtained from several of these patients before P. aeruginosa colonization or infection of these individuals was detected, which provided an opportunity to evaluate their responsiveness to pseudomonal exoproducts as they acquired the organism. Exotoxin A was purified from culture supernatant fluids of strain PA-103, and the two proteases were purified from an isolate of strain JR3, a highly proteolytic strain originally recovered from the sputum of a cystic fibrosis patient. Antibodies to the exotoxin A and the two proteases were detected in these sera, and sera which contained relatively high antibody levels to exotoxin A afforded mice complete protection against lethal challenges with this substance. Statistical analyses showed that patients infected with P. aeruginosa had consistently higher antibody levels (P less than 0.005) to the exoproducts than patients who were colonized with this organism. Also, patients colonized with P. aeruginosa possessed significantly higher antibody levels (P less than 0.003) to these three exoproducts than uninfected, hospitalized patients. Parke-Davis type 1 was the strain most commonly isolated from these patients (46%), but colonization or infection due to this organism usually resulted in the production of low levels of antibody to Pseudomonas exoproducts. However, infections with Parke-David type 7 organisms were always associated with intermediate- and high-responder sera to exotoxin A. These results indicated that potentially toxic products were elaborated during the course of cancer-related colonization and infection with P. aeruginosa.
我们分析了28例患有各种恶性肿瘤患者的血清,以检测抗铜绿假单胞菌外毒素A和两种假单胞菌蛋白酶抗体的出现情况。在研究期间,这些个体中有27人曾一度被铜绿假单胞菌定植或感染,而其余患者则被4种非铜绿假单胞菌属的假单胞菌定植。在检测到这些个体被铜绿假单胞菌定植或感染之前,从其中一些患者身上获取了血清,这为评估他们在感染该菌时对假单胞菌外毒素产物的反应能力提供了机会。外毒素A从PA - 103菌株的培养上清液中纯化得到,两种蛋白酶从JR3菌株的分离株中纯化得到,JR3菌株是一种高蛋白酶活性菌株,最初从一名囊性纤维化患者的痰液中分离得到。在这些血清中检测到了针对外毒素A和两种蛋白酶的抗体,含有相对高浓度抗外毒素A抗体的血清能使小鼠完全免受该物质的致死性攻击。统计分析表明,感染铜绿假单胞菌的患者对外毒素产物的抗体水平始终高于被该菌定植的患者(P<0.005)。此外,被铜绿假单胞菌定植的患者对这三种外毒素产物的抗体水平显著高于未感染的住院患者(P<0.003)。Parke - Davis 1型是从这些患者中最常分离出的菌株(46%),但该菌的定植或感染通常导致针对假单胞菌外毒素产物产生低水平抗体。然而,感染Parke - David 7型菌株总是与对外毒素A的中、高反应性血清相关。这些结果表明,在与癌症相关的铜绿假单胞菌定植和感染过程中会产生潜在的毒性产物。